- Home
- AKRO
as 05-09-2025 4:00pm EST
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
Upcoming Earnings Alert:
Get ready for potential market movements as Akero Therapeutics Inc. AKRO prepares to release earnings report on 16 May 2025.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.8B | IPO Year: | 2019 |
| Target Price: | $76.29 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.86 - $58.40 | Next Earning Date: | 05-16-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Akero Therapeutics Inc. (AKRO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rolph Timothy | AKRO | Chief Scientific Officer | Apr 24 '25 | Sell | $41.03 | 6,250 | $256,437.50 | 169,721 | |
| Yale Catriona | AKRO | Chief Development Officer | Apr 15 '25 | Sell | $38.21 | 9,073 | $343,962.22 | 95,034 | |
| Cheng Andrew | AKRO | President and CEO | Apr 10 '25 | Sell | $35.23 | 30,000 | $1,056,780.00 | 624,324 | |
| Rolph Timothy | AKRO | Chief Scientific Officer | Apr 7 '25 | Sell | $36.56 | 6,250 | $224,261.50 | 169,721 | |
| Graham G. Walmsley | AKRO | Director | Mar 25 '25 | Buy | $43.77 | 200,000 | $8,787,921.11 | 1,150,000 | |
| Yale Catriona | AKRO | Chief Development Officer | Mar 17 '25 | Sell | $44.87 | 10,000 | $447,605.05 | 95,034 | |
| White William Richard | AKRO | Chief Financial Officer | Mar 12 '25 | Sell | $44.88 | 676 | $30,338.88 | 61,959 | |
| Yale Catriona | AKRO | Chief Development Officer | Mar 12 '25 | Sell | $44.88 | 614 | $27,556.32 | 95,034 | |
| Young Jonathan | AKRO | Chief Operating Officer | Mar 12 '25 | Sell | $44.88 | 607 | $27,242.16 | 200,540 | |
| Cheng Andrew | AKRO | President and CEO | Mar 12 '25 | Sell | $44.88 | 1,738 | $78,001.44 | 624,324 |
Latest Akero Therapeutics Inc. News
AKRO Breaking Stock News: Dive into AKRO Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 hours ago
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
GlobeNewswire
16 hours ago
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
GlobeNewswire
2 days ago
Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference
GlobeNewswire
10 days ago
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025
MT Newswires
a month ago
Akero Therapeutics Insider Bought Shares Worth $8,787,921, According to a Recent SEC Filing
MT Newswires
2 months ago
Akero Therapeutics Insider Sold Shares Worth $2,243,213, According to a Recent SEC Filing
Zacks
2 months ago
Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?
Insider Monkey
2 months ago
Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025
Compare AKRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AKRO Akero Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.